Right now, Gerald's credibility only matters as it pertains to potential partners. Once a partner is named, all of this debate about complex statistics will be in the rear view mirror and forgotten. Even if his blog doesn't satisfy laymen investors tomorrow, it will only impact the share price until the partnership is announced. Then everybody will realize how stupid it was to panic sell last week and jump back on the bandwagon. Funniest part is that the same people who criticize Gerald now will be his biggest fans when that time comes. Nothing has changed. Everything is still on track, just taking longer than expected. If you actually look at the total package, things are becoming more and more clear despite the rhetoric from those who didn't understand last week's events. The addition of Huffman who specializes in mergers, acquisitions, and spin-offs was a pretty clear signal. The licensing of Dr. Arendt's work was too. There's no way they would be proceeding this way if they felt Lympro was going to fail. Tomorrow is only a make or break day for GC's credibility to those that are either too dumb or too blind to see what's going on here.